Notable Tuesday Option Activity: LLY, CRWD, MRNA

Significant options activity was recorded in CrowdStrike (CRWD) and Moderna (MRNA) today: CRWD saw 11,577 contracts (~1.2M underlying shares), about 47.4% of its 30‑day ADTV (2.4M shares), led by 726 contracts in the $490 call expiring Jan 2, 2026 (~72,600 shares). MRNA had 48,465 contracts (~4.8M underlying shares), roughly 46.3% of its 30‑day ADTV (10.5M), driven by 14,786 contracts in the $33 Jan 2, 2026 call (~1.5M shares). These concentrated long‑dated call flows could indicate sizeable bullish positioning or hedging interest but are reported here as market flow data rather than company fundamentals.

Analysis

Market structure: Concentrated long-dated call flow (CRWD 726 contracts at $490; MRNA 14,786 contracts at $33) signals institutional demand for asymmetric upside in single names rather than broad beta. Dealers who sold these calls will carry net short-delta/gamma exposure, triggering systematic delta-hedging that can mechanically lift the underlying into the near term; MRNA’s ~1.5M underlying-equivalent today (~46% of ADV) is large enough to matter to intraday/weekly price action. This selectively tightens call supply, steepens skew and raises implied vols on those names while leaving broader rates/FX/commodities largely unaffected except via risk‑on transmission to credit spreads and equity carry trades.

Risk assessment: Tail risks include binary clinical/regulatory events for MRNA and a large enterprise spending slowdown or major breach for CRWD; either would vaporize long-dated call premia and cause sharp IV spikes and mean reversion. Time horizons: immediate (days) = dealer hedging/IV repricing; short (weeks–months) = position roll/earnings/FDA catalysts; long (12+ months) = fundamental re-rating or M&A outcomes by Jan 2026. Hidden dependencies: flows may be structured products, corporate hedges, or block trades—if these are hedged synthetically the directional signal may be overstated.

Trade implications: Treat MRNA as a directional signal with defined-risk option exposure rather than outright stock chase; use long-dated call spreads to capture upside while capping premium. For CRWD the $490 activity is small in share terms and likely speculative—prefer selling short-dated premium or use small, defined-risk bullish spreads only after confirming dealer-driven lift. Size positions conservatively: 0.5–2% portfolio allocations depending on conviction and hedge capacity.

Contrarian angles: The market may be interpreting large call volume as pure bullish conviction when it could be volatility/dispersion trades or corporate hedges; if that’s true, buying more exposure risks being short delta into IV compression. Historical parallels: clustered long-dated OTM call accumulation often precedes either takeover rumors or disappointment-driven IV collapses; unintended consequence is that dealer gamma hedging amplifies a move up then forces violent downside when hedges are unwound. Monitor flow continuity (3+ trading days) before scaling in.

Key Decisions for Investors

• Buy a defined‑risk MRNA Jan 02 2026 $33/$50 call spread sized to 1–1.5% of portfolio (max loss = premium). Take profit at 2x premium or if MRNA > $50; stop-loss/exit if MRNA < $25 by 31 Mar 2025 or IV falls >40% from today.
• Do not chase CRWD Jan‑2026 OTM $490 calls. Instead sell 6–12 week CRWD call spreads ~10–15% OTM (size 0.5% portfolio) to collect premium; close if underlying gaps >20% in 3 trading days or implied vol for short‑dated calls drops >30%.
• If aggregated single‑name call buying >30% of ADV persists for any ticker for 3 consecutive trading days, increase cash/gamma hedge by 1–2% and trim unhedged long biotech exposure (e.g., reduce MRNA/peer equities by 1%) to limit forced liquidation risk.
• Watch four near‑term catalysts before scaling: MRNA clinical/FDA calendar over next 90–180 days; CRWD enterprise earnings/guidance in next 60–120 days; any block‑trade prints >100k underlying continuing for 3+ days; volatility/skew moves >25% intraday—use these as hard signals to add or unwind positions.